Back to search

Peptide record

TPDB42931

P01 Anticancer standard
16 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB42931
P01
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 16-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
Sequence
SETAPAAPAAPAPAEK
Physicochemical Analysis
C64H103N17O23
RNDCQGHILMFWYV
A
1478.62
4.26
1
2
7
-1
5.91
-0.388
43.75
Mammalian: 1.9 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
2
Residue Composition
number
7
A
0
R
0
N
0
D
0
C
2
E
0
Q
0
G
0
H
0
I
0
L
1
K
0
M
0
F
4
P
1
S
1
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 7 R: 0 N: 0 D: 0 C: 0 E: 2 Q: 0 G: 0 H: 0 I: 0 L: 0 K: 1 M: 0 F: 0 P: 4 S: 1 T: 1 W: 0 Y: 0 V: 0
Chemical Descriptors
16
C64H103N17O23
1478.62
4.26
-1
5.91
-0.388
Free
L
Linear
Free
Anticancer
Histone H1.4 (H1-4) Fragment
Evidence Records 2 records
Evidence 1 Activity

Activity

Relative viability
Relative viability = 0.84 at 50 µg/ml
Anticancer

Target

Bone Cancer
MG-63
Bone

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

Relative viability
Relative viability = 1.13 at 50 µg/ml
Anticancer

Target

Bone Cancer
U-2 OS
Bone

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023